article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

Professor Dinesh Khanna, Frederick GL Huetwell Professor of Rheumatology and Director, Scleroderma Program at the University of Michigan said: “The mechanism of action for FT011 offers an important point of difference for the scleroderma research field as the upstream inhibition of inflammation and fibrosis may offer meaningful clinical outcomes.

article thumbnail

Scepticism in press over Kintor’s COVID-19 US drug trial

pharmaphorum

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. Kintor is in talks with the Brazilian health regulator Anvisa about a further trials.

article thumbnail

STAT+: Pharmalittle: Private equity moving to buy clinical trials firms; data provider limits media access to drug prices

STAT News

And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies. And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies.